Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516566 | 0.88 | GSK3A (0.40) | ALPLDGAT1GSK3AGSK3BPDGFRB | |
| SCHEMBL24576804 | 0.79 | ALPL (0.47) | ALPLDGAT1GSK3AGSK3BPDGFRB | |
| SCHEMBL17419148 | 0.78 | ALPL (0.45) | ALPLDGAT1GSK3AGSK3BPDGFRB | |
| SCHEMBL798868 | 0.77 | ALPL (0.45) | ALPLDGAT1GSK3AGSK3BPDGFRB | |
| SCHEMBL20472729 | 0.76 | ALPL (0.44) | ALPLDGAT1GSK3AGSK3BPDGFRB | |
| SCHEMBL3513930 | 0.76 | ALPL (0.44) | ALPLDGAT1GSK3AGSK3BPDGFRB | |
| SCHEMBL789862 | 0.75 | ALPL (0.46) | ALPLDGAT1GSK3AGSK3BPDGFRB | |
| SCHEMBL29604061 | 0.75 | ALPL (0.46) | ALPLDGAT1GSK3AGSK3BPDGFRB | |
| SCHEMBL3668559 | 0.74 | ALPL (0.46) | ALPLDGAT1GSK3AGSK3BPDGFRB | |
| SCHEMBL29504617 | 0.74 | ALPL (0.46) | ALPLDGAT1GSK3AGSK3BPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | ALPL 2385/4885DGAT1 989/4885GSK3A 700/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | ALPL 2385/4885DGAT1 989/4885GSK3A 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.